SeaCrest Wealth Management’s Takeda Pharmaceutical TAK Stock Holding History

SeaCrest Wealth Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,621	Closed	-$53K	–	1689
2019 Q1	$53K	Buy	2,621 +2,582	+6,621%	+$52K	0.01%	917
2018 Q4	$1K	Buy	+39	New	+$658	﹤0.01%	2067

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SeaCrest Wealth Management's TAK Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Takeda Pharmaceutical (TAK) in Q2 2019, closing a stake of 2,621 shares — an estimated $53K sold.

SeaCrest Wealth Management first reported a position in TAK in Q4 2018 and held it in 2 quarters. The position peaked at $53K in Q1 2019. 347 funds tracked by Wall St. Rank hold TAK as of Q2 2019.

SeaCrest Wealth Management reported no remaining Takeda Pharmaceutical position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 2,621 Takeda Pharmaceutical shares in Q2 2019, an estimated $53K.
SeaCrest Wealth Management first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 2 quarters.
SeaCrest Wealth Management's Takeda Pharmaceutical position peaked at $53K in Q1 2019.
347 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.